Related Experiment Video
Updated: Jul 19, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Valproic acid does not affect markers of human immunodeficiency virus disease progression
Beau M Ances1, Scott Letendre, Maria Buzzell
1Department of Neurosciences, University of California, San Diego, California, USA. bances@ucsd.edu
Abstract:
Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Therapeutic Drug Monitoring: Affecting Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

